-
Product Insights
Esophagitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophagitis - Drugs In Development, 2023’, provides an overview of the Esophagitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TR-8 in Multiple Sclerosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TR-8 in Multiple Sclerosis Drug Details:TR-8 is under development for the treatment of Crohn's disease and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceclazepide in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ceclazepide in Pancreatic Cancer Drug Details:Ceclazepide (TR-2A) is under development for the treatment of gastro-oesophageal reflux...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceclazepide in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ceclazepide in Gastric Cancer Drug Details:Ceclazepide (TR-2A) is under development for the treatment of gastro-oesophageal reflux...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceclazepide in Reflux Esophagitis (Gastroesophageal Reflux Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ceclazepide in Reflux Esophagitis (Gastroesophageal Reflux Disease) Drug Details:Ceclazepide (TR-2A) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceclazepide in Barretts Esophagus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ceclazepide in Barretts EsophagusDrug Details:Ceclazepide (TR-2A) is under development for the treatment of gastro-oesophageal reflux disease,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-3994 in Diastolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-3994 in Diastolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PL-3994 in Diastolic Heart FailureDrug Details:PL-3994 is under development for the treatment...
-
Product Insights
Renal Denervation Catheters Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Renal Denervation Catheters Pipeline Market Report Overview Renal denervation is also known as renal sympathetic denervation (RSD). It is a minimally invasive, catheter-based endovascular procedure that utilizes radiofrequency energy or ultrasound energy to ablate nerves in the walls of the renal artery, causing a reduction in nerve activity which ultimately reduces the blood pressure in patients with resistant hypertension. The Renal Denervation Catheters pipeline market research report provides comprehensive information about the Renal Denervation Catheters pipeline products with a comparative...
-
Product Insights
Structural Heart Occluders Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Structural Heart Occluders Pipeline Market Report Overview Structural heart occluders are used for the treatment of congenital heart defects by closing openings in the heart. Structural heart occluders cover left atrial appendage closure devices, atrial septal defect occluders, ventricular septal defect occluders, patent foramen ovale closure devices, and patent ductus arteriosus closure devices. The structural heart occluders pipeline market research report provides comprehensive information about the structural heart occluders pipeline products with a comparative analysis of the products at various...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Muscle Invasive Bladder Cancer (MIBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Muscle Invasive Bladder Cancer (MIBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Muscle Invasive Bladder Cancer (MIBC) Drug Details:...